MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ
0.3500
+0.0097
+2.85%
Opening 14:03 12/09 EST
OPEN
0.3403
PREV CLOSE
0.3403
HIGH
0.3800
LOW
0.3403
VOLUME
18.17K
TURNOVER
2.53K
52 WEEK HIGH
1.230
52 WEEK LOW
0.3400
MARKET CAP
14.04M
P/E (TTM)
-1.6107
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 6d ago
Why DraftKings Shares Are Trading Lower By 5%; Here Are 24 Stocks Moving Premarket
Benzinga · 11/28 12:38
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 11/28 12:28
Alterity Therapeutics Announced Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
Benzinga · 11/07 10:27
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and updat...
PR Newswire · 10/28 11:25
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/20 21:57
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the S...
PR Newswire · 10/13 14:25
Alterity Therapeutics Starts Multiple System Atrophy Trial in Australia After Regulatory Nod
Alterity Therapeutics Starts Multiple System Atrophy Trial in Australia After Regulatory Nod
MT Newswires · 10/13 11:27
More
About ATHE
Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes. ATH434 has been granted Orphan Drug designation for the treatment of Multiple System Atrophy.

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.